<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00259272</url>
  </required_header>
  <id_info>
    <org_study_id>9675</org_study_id>
    <secondary_id>F1D-FP-S057</secondary_id>
    <nct_id>NCT00259272</nct_id>
  </id_info>
  <brief_title>Validation of Multidimensional Assessment of THYmic States (MATHYS): A Study in a Population of Bipolar Patients Treated With Olanzapine</brief_title>
  <official_title>Phase IIIb, Multicenter, Single-Arm Open-Label Study, Supporting the Development and the Validation of the MATHYS Scale (Multidimensional Assessment of THYmic States) in a Population of Bipolar Patients Treated With Olanzapine, Either in-Label (Manic and Mixed Patients) and Off-Label (Hypomanic and Bipolar Depression)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A non randomized study to validate the MATHYS Scale in a population of in and outpatients
      greater than or equal to 18 years of age, suffering from Bipolar Disorder I or II, and
      treated with olanzapine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Changes From Baseline to 6 Week and 24 Week Endpoints in the Multidimensional Assessment of THYmic States Scale (MATHYS) Total Score</measure>
    <time_frame>Baseline, 6 Weeks, 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline MATHYS Assessment - Principal Component Analysis and Orthogonal Transformation Matrix</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to 6 Week and 24 Week Endpoints in the Hamilton 17-Items Depression Scale (HAMD-17) Total Score</measure>
    <time_frame>Baseline, 6 Weeks, 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to 6 Week and 24 Week Endpoints in the Hamilton Anxiety Scale (HAMA) Total Score</measure>
    <time_frame>Baseline, 6 Weeks, 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to 6 Week and 24 Week Endpoints in the Young Mania Rating Scale (YMRS) Total Score</measure>
    <time_frame>Baseline, 6 Weeks, 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to 24 Week Endpoint in Glycaemia Levels (Glucose Fasting Levels)</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increases and Decreases in Fasting Glucose Levels</measure>
    <time_frame>over 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to 24 Week Endpoint in Lipids</measure>
    <time_frame>Baseline and 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increases and Decreases in Lipid Levels</measure>
    <time_frame>over 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to 24 Week Endpoint in Weight</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight Gain Compared to Baseline</measure>
    <time_frame>over 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wellness Interventional Program for Weight Gain Management in Patients (for Those Who Gain at Anytime More Than 7% of Body Weight, Compared to Baseline)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MATHYS Total Score at Baseline - According to Thymic Reactivity Assessment</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 6 Week and 24 Week Endpoints in HAMA Total Scores - According to Thymic Reactivity Assessment</measure>
    <time_frame>Baseline, 6 Weeks, 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 6 Week and 24 Week Endpoints in HAMD-17 Total Scores - According to Thymic Reactivity Assessment</measure>
    <time_frame>Baseline, 6 Weeks, 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 6 Week and 24 Week Endpoints in YMRS Total Scores - According to Thymic Reactivity Assessment</measure>
    <time_frame>Baseline, 6 Weeks, 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional Reactivity With the Physiological Measure of Heart Rate</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional Reactivity With the Physiological Measure of Skin Conductance</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional Reactivity With the Physiological Measure of Startle Reflex Response - Latency of Blink</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional Reactivity With the Physiological Measure of Startle Reflex Response - Amplitude of Blink</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Bipolar Disorder I or II</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine</intervention_name>
    <description>5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>LY170053</other_name>
    <other_name>Velotab</other_name>
    <other_name>Zydis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must meet Diagnostic and Statistical Manual of Mental Disorders, Fourth
             Edition, Text Revision (DSM-IV-TR) disease diagnostic criteria for Bipolar Disorder

               -  currently or most recently in a Manic Episode (Single Manic Episode or Most
                  Recent Episode Manic) or

               -  currently or most recently in a Hypomanic Episode or

               -  currently or most recently in a Mixed Episode or

               -  currently or most recently in a Major Depressive Episode

               -  and confirmed by the module D of the SCID (Semi-Structured Interview).

          2. Patients must be more than 18 of age at Visit 0.

        Exclusion Criteria:

          1. A valid current or lifetime DSM-IV-TR Axis I or II diagnosis which could interfere, at
             the investigator's opinion, with the evaluation.

          2. Patients on antidepressant or mood stabilizer therapy one week (four weeks with
             fluoxetine) prior to Visit 1, with the exception of mood stabilizer therapy considered
             in the opinion of the investigator as an efficient treatment for at least one year
             prior to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT-5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Andilly</city>
        <zip>95580</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cornebarrieu</city>
        <zip>31700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Rochelle</city>
        <zip>17000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Seyne Sur Mer</city>
        <zip>83500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lyon</city>
        <zip>69322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Montpellier</city>
        <zip>34094</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Orvault</city>
        <zip>44700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pin Balma</city>
        <zip>31130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plaisir</city>
        <zip>78373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2005</study_first_submitted>
  <study_first_submitted_qc>November 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2005</study_first_posted>
  <results_first_submitted>April 30, 2009</results_first_submitted>
  <results_first_submitted_qc>April 30, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 24, 2009</results_first_posted>
  <last_update_submitted>April 30, 2009</last_update_submitted>
  <last_update_submitted_qc>April 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All participants received olanzapine and were grouped according to their most recent type of episode.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Manic Episode</title>
          <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
        </group>
        <group group_id="P2">
          <title>Hypomanic Episode</title>
          <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 10 mg)</description>
        </group>
        <group group_id="P3">
          <title>Mixed Episode</title>
          <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
        </group>
        <group group_id="P4">
          <title>Depressive Episode</title>
          <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 5 mg).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Manic Episode</title>
          <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
        </group>
        <group group_id="B2">
          <title>Hypomanic Episode</title>
          <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 10 mg)</description>
        </group>
        <group group_id="B3">
          <title>Mixed Episode</title>
          <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
        </group>
        <group group_id="B4">
          <title>Depressive Episode</title>
          <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 5 mg).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="48"/>
            <count group_id="B5" value="141"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.39" spread="15.32"/>
                    <measurement group_id="B2" value="45.81" spread="11.68"/>
                    <measurement group_id="B3" value="46.62" spread="12.87"/>
                    <measurement group_id="B4" value="44.35" spread="11.98"/>
                    <measurement group_id="B5" value="45.61" spread="12.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnostic Summary</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bipolar Disorder I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bipolar Disorder II - Hypomanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bipolar Disorder II - Depressed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Lifetime Suicide Attempts</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Missing Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with at Least One Episode of Depression</title>
          <description>Presence of at least one previous episode was defined as: number of episodes in the past 12 months reported and/or number of episodes lifetime reported and/or year of onset of the first symptoms reported.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Missing Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with at Least One Episode of Hypomania</title>
          <description>Presence of at least one previous episode was defined as: number of episodes in the past 12 months reported and/or number of episodes lifetime reported and/or year of onset of the first symptoms reported.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Missing Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with at Least One Episode of Mania</title>
          <description>Presence of at least one previous episode was defined as: number of episodes in the past 12 months reported and/or number of episodes lifetime reported and/or year of onset of the first symptoms reported.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Missing Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with at Least One Episode of Mixed Episode</title>
          <description>Presence of at least one previous episode was defined as: number of episodes in the past 12 months reported and/or number of episodes lifetime reported and/or year of onset of the first symptoms reported.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Missing Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Inpatient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outpatient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Central Nervous System Treatment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Suicide Ideation</title>
          <description>Assessed via the 17-item Hamilton Depression Rating Scale (HAMD-17) item 3. Item 3 assesses presence and level of suicidal ideations.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0: Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1: Feels Life Not Worth Living</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2:Wishes He Were Dead or Thoughts of Death to Self</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3: Suicide Ideas or Gestures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4: Attempts Suicide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Thymic Reactivity - Investigator-Based Assessment</title>
          <description>Investigators were asked - according to your clinical experience, is the patient with: neither; thymic hyper-reactivity; or thymic hypo-reactivity.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Neither</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thymic Hyper-Reactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thymic Hypo-Reactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at Time of Onset of First Episode</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.57" spread="13.94"/>
                    <measurement group_id="B2" value="34.00" spread="13.75"/>
                    <measurement group_id="B3" value="27.36" spread="10.78"/>
                    <measurement group_id="B4" value="29.19" spread="10.41"/>
                    <measurement group_id="B5" value="30.29" spread="12.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>Body mass index is an estimate of body fat based on body weight divided by height squared.</description>
          <units>kilogram per meter squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.80" spread="4.53"/>
                    <measurement group_id="B2" value="24.73" spread="4.98"/>
                    <measurement group_id="B3" value="26.86" spread="7.75"/>
                    <measurement group_id="B4" value="24.54" spread="3.70"/>
                    <measurement group_id="B5" value="25.09" spread="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Current Episode</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.99" spread="1.51"/>
                    <measurement group_id="B2" value="1.95" spread="3.22"/>
                    <measurement group_id="B3" value="1.71" spread="1.56"/>
                    <measurement group_id="B4" value="1.51" spread="1.49"/>
                    <measurement group_id="B5" value="1.53" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Illness</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.86" spread="13.93"/>
                    <measurement group_id="B2" value="12.45" spread="9.52"/>
                    <measurement group_id="B3" value="19.28" spread="14.54"/>
                    <measurement group_id="B4" value="15.70" spread="11.59"/>
                    <measurement group_id="B5" value="15.91" spread="12.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.83" spread="12.34"/>
                    <measurement group_id="B2" value="69.89" spread="14.71"/>
                    <measurement group_id="B3" value="74.42" spread="20.00"/>
                    <measurement group_id="B4" value="70.85" spread="14.41"/>
                    <measurement group_id="B5" value="70.78" spread="15.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Changes From Baseline to 6 Week and 24 Week Endpoints in the Multidimensional Assessment of THYmic States Scale (MATHYS) Total Score</title>
        <description>A visual analogic scale consisting of 20 items. Item scores vary from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state), except for items 5 to 10 and 17 and 18 which are inversed and are consequently to be reversed before the analysis. Total score is sum of the 20 items and can vary from 0 to 200.</description>
        <time_frame>Baseline, 6 Weeks, 24 weeks</time_frame>
        <population>Intention to treat. Number of participants with baseline and at least one non-missing postbaseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Manic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O2">
            <title>Hypomanic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 10 mg)</description>
          </group>
          <group group_id="O3">
            <title>Mixed Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O4">
            <title>Depressive Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 5 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Changes From Baseline to 6 Week and 24 Week Endpoints in the Multidimensional Assessment of THYmic States Scale (MATHYS) Total Score</title>
          <description>A visual analogic scale consisting of 20 items. Item scores vary from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state), except for items 5 to 10 and 17 and 18 which are inversed and are consequently to be reversed before the analysis. Total score is sum of the 20 items and can vary from 0 to 200.</description>
          <population>Intention to treat. Number of participants with baseline and at least one non-missing postbaseline value.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=34, 31, 25, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.55" spread="22.18"/>
                    <measurement group_id="O2" value="136.52" spread="22.45"/>
                    <measurement group_id="O3" value="116.74" spread="21.30"/>
                    <measurement group_id="O4" value="76.88" spread="22.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Week Endpoint (n=31, 31, 25, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.37" spread="23.09"/>
                    <measurement group_id="O2" value="105.15" spread="23.10"/>
                    <measurement group_id="O3" value="101.58" spread="22.55"/>
                    <measurement group_id="O4" value="93.41" spread="23.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from 6 Week Endpoint (n=30, 31, 24, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.91" spread="28.70"/>
                    <measurement group_id="O2" value="-31.37" spread="30.46"/>
                    <measurement group_id="O3" value="-13.32" spread="26.37"/>
                    <measurement group_id="O4" value="17.17" spread="26.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Week Endpoint (n=35, 31, 26, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.15" spread="24.84"/>
                    <measurement group_id="O2" value="103.16" spread="23.03"/>
                    <measurement group_id="O3" value="91.56" spread="25.19"/>
                    <measurement group_id="O4" value="94.58" spread="27.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from 24 Week Endpoint (n=34, 31, 25, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.67" spread="24.83"/>
                    <measurement group_id="O2" value="-33.36" spread="33.61"/>
                    <measurement group_id="O3" value="-26.08" spread="40.51"/>
                    <measurement group_id="O4" value="17.04" spread="31.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to 6 Week and 24 Week Endpoints in the Hamilton 17-Items Depression Scale (HAMD-17) Total Score</title>
        <description>The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (not at all depressed) to 52 (severely depressed).</description>
        <time_frame>Baseline, 6 Weeks, 24 Weeks</time_frame>
        <population>Intention to treat. Number of participants with baseline and at least one non-missing postbaseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Manic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O2">
            <title>Hypomanic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 10 mg)</description>
          </group>
          <group group_id="O3">
            <title>Mixed Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O4">
            <title>Depressive Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 5 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 6 Week and 24 Week Endpoints in the Hamilton 17-Items Depression Scale (HAMD-17) Total Score</title>
          <description>The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (not at all depressed) to 52 (severely depressed).</description>
          <population>Intention to treat. Number of participants with baseline and at least one non-missing postbaseline value.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=35, 30, 26, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.46" spread="4.86"/>
                    <measurement group_id="O2" value="8.43" spread="5.33"/>
                    <measurement group_id="O3" value="12.65" spread="4.83"/>
                    <measurement group_id="O4" value="16.06" spread="7.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from 6 Week Endpoint (n=29, 29, 25, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.79" spread="4.59"/>
                    <measurement group_id="O2" value="-3.10" spread="4.59"/>
                    <measurement group_id="O3" value="-5.60" spread="6.60"/>
                    <measurement group_id="O4" value="-8.51" spread="6.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from 24 Week Endpoint (n=34, 30, 26, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.74" spread="5.02"/>
                    <measurement group_id="O2" value="-3.20" spread="6.40"/>
                    <measurement group_id="O3" value="-5.50" spread="6.72"/>
                    <measurement group_id="O4" value="-7.96" spread="7.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to 6 Week and 24 Week Endpoints in the Hamilton Anxiety Scale (HAMA) Total Score</title>
        <description>The 14-item HAMA assesses the severity of anxiety. The investigator talked to the patient about their symptoms over the previous week before the study visit. Each item was scored using a 5-point scale, i.e. 0 = absent to 4 = severe. The total score of HAMA-14 may range from 0 (not present) to 56 (very severe).</description>
        <time_frame>Baseline, 6 Weeks, 24 Weeks</time_frame>
        <population>Intention to treat. Number of participants with baseline and at least one non-missing postbaseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Manic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O2">
            <title>Hypomanic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 10 mg)</description>
          </group>
          <group group_id="O3">
            <title>Mixed Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O4">
            <title>Depressive Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 5 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 6 Week and 24 Week Endpoints in the Hamilton Anxiety Scale (HAMA) Total Score</title>
          <description>The 14-item HAMA assesses the severity of anxiety. The investigator talked to the patient about their symptoms over the previous week before the study visit. Each item was scored using a 5-point scale, i.e. 0 = absent to 4 = severe. The total score of HAMA-14 may range from 0 (not present) to 56 (very severe).</description>
          <population>Intention to treat. Number of participants with baseline and at least one non-missing postbaseline value.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=36, 31, 26, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.78" spread="6.29"/>
                    <measurement group_id="O2" value="11.94" spread="7.73"/>
                    <measurement group_id="O3" value="15.46" spread="7.17"/>
                    <measurement group_id="O4" value="15.08" spread="7.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from 6 Week Endpoint (n=31, 31, 25, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.68" spread="4.85"/>
                    <measurement group_id="O2" value="-5.48" spread="5.89"/>
                    <measurement group_id="O3" value="-7.32" spread="6.31"/>
                    <measurement group_id="O4" value="-6.76" spread="6.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from 24 Week Endpoint (n=35, 31, 26, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.26" spread="4.80"/>
                    <measurement group_id="O2" value="-5.65" spread="7.36"/>
                    <measurement group_id="O3" value="-7.62" spread="7.87"/>
                    <measurement group_id="O4" value="-6.83" spread="7.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to 6 Week and 24 Week Endpoints in the Young Mania Rating Scale (YMRS) Total Score</title>
        <description>The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.</description>
        <time_frame>Baseline, 6 Weeks, 24 Weeks</time_frame>
        <population>Intention to treat. Number of participants with baseline and at least one non-missing postbaseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Manic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O2">
            <title>Hypomanic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 10 mg)</description>
          </group>
          <group group_id="O3">
            <title>Mixed Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O4">
            <title>Depressive Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 5 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 6 Week and 24 Week Endpoints in the Young Mania Rating Scale (YMRS) Total Score</title>
          <description>The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.</description>
          <population>Intention to treat. Number of participants with baseline and at least one non-missing postbaseline value.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=36, 31, 25, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.50" spread="10.34"/>
                    <measurement group_id="O2" value="17.84" spread="4.88"/>
                    <measurement group_id="O3" value="12.96" spread="7.69"/>
                    <measurement group_id="O4" value="2.78" spread="3.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from 6 Week Endpoint (n=31, 31, 24, 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.65" spread="9.38"/>
                    <measurement group_id="O2" value="-13.13" spread="6.02"/>
                    <measurement group_id="O3" value="-9.67" spread="7.91"/>
                    <measurement group_id="O4" value="-0.86" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from 24 Week Endpoint (n=35, 31, 25, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.00" spread="10.94"/>
                    <measurement group_id="O2" value="-14.45" spread="7.36"/>
                    <measurement group_id="O3" value="-10.60" spread="7.95"/>
                    <measurement group_id="O4" value="-0.82" spread="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to 24 Week Endpoint in Glycaemia Levels (Glucose Fasting Levels)</title>
        <time_frame>baseline and 24 weeks</time_frame>
        <population>Safety Population. All participants having been prescribed at least one dose of study drug. Number of participants with baseline and at least one non-missing postbaseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Manic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O2">
            <title>Hypomanic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 10 mg)</description>
          </group>
          <group group_id="O3">
            <title>Mixed Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O4">
            <title>Depressive Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 5 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 24 Week Endpoint in Glycaemia Levels (Glucose Fasting Levels)</title>
          <population>Safety Population. All participants having been prescribed at least one dose of study drug. Number of participants with baseline and at least one non-missing postbaseline value.</population>
          <units>milligrams per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=33, 30, 23, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.27" spread="16.31"/>
                    <measurement group_id="O2" value="85.99" spread="11.33"/>
                    <measurement group_id="O3" value="85.94" spread="12.58"/>
                    <measurement group_id="O4" value="88.52" spread="13.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from 24 Week Endpoint (n=26, 28, 23, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.07" spread="16.15"/>
                    <measurement group_id="O2" value="4.65" spread="15.32"/>
                    <measurement group_id="O3" value="3.89" spread="9.62"/>
                    <measurement group_id="O4" value="7.31" spread="30.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increases and Decreases in Fasting Glucose Levels</title>
        <time_frame>over 24 weeks</time_frame>
        <population>Safety Population. All participants having been prescribed at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Manic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O2">
            <title>Hypomanic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 10 mg)</description>
          </group>
          <group group_id="O3">
            <title>Mixed Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O4">
            <title>Depressive Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 5 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Increases and Decreases in Fasting Glucose Levels</title>
          <population>Safety Population. All participants having been prescribed at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Least One Increase in Fasting Glucose (FG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Least One Decrease in FG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Least One Increase/Decrease in FG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients Who Increase and Decrease During Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to 24 Week Endpoint in Lipids</title>
        <description>Baseline, change from baseline, and percent change for the following lipids are presented: Total Cholesterol (TC), High Density Lipoproteins (HDL), Low Density Lipoproteins (LDL), and Triglycerides (TG).</description>
        <time_frame>Baseline and 24 Weeks</time_frame>
        <population>Safety Population. All participants having been prescribed at least one dose of study drug. Number of participants with baseline and at least one non-missing postbaseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Manic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O2">
            <title>Hypomanic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 10 mg)</description>
          </group>
          <group group_id="O3">
            <title>Mixed Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O4">
            <title>Depressive Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 5 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 24 Week Endpoint in Lipids</title>
          <description>Baseline, change from baseline, and percent change for the following lipids are presented: Total Cholesterol (TC), High Density Lipoproteins (HDL), Low Density Lipoproteins (LDL), and Triglycerides (TG).</description>
          <population>Safety Population. All participants having been prescribed at least one dose of study drug. Number of participants with baseline and at least one non-missing postbaseline value.</population>
          <units>milligrams per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TC Baseline (n=33, 30, 24, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182.88" spread="41.88"/>
                    <measurement group_id="O2" value="191.55" spread="42.49"/>
                    <measurement group_id="O3" value="210.51" spread="50.78"/>
                    <measurement group_id="O4" value="203.77" spread="44.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in TC from 24 Week Endpoint (n=26,28,23,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.64" spread="33.95"/>
                    <measurement group_id="O2" value="2.26" spread="27.25"/>
                    <measurement group_id="O3" value="7.03" spread="30.77"/>
                    <measurement group_id="O4" value="4.41" spread="50.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change in TC (n=26, 28, 23, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.96" spread="19.57"/>
                    <measurement group_id="O2" value="3.10" spread="13.83"/>
                    <measurement group_id="O3" value="4.41" spread="16.97"/>
                    <measurement group_id="O4" value="4.68" spread="23.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Baseline (n=33, 30, 23, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.21" spread="14.65"/>
                    <measurement group_id="O2" value="56.87" spread="16.77"/>
                    <measurement group_id="O3" value="57.46" spread="19.13"/>
                    <measurement group_id="O4" value="50.78" spread="13.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in HDL from Endpoint (n=26, 28, 22, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="13.32"/>
                    <measurement group_id="O2" value="1.57" spread="13.14"/>
                    <measurement group_id="O3" value="-0.45" spread="16.27"/>
                    <measurement group_id="O4" value="3.25" spread="12.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change in HDL (n=26, 28, 22, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.04" spread="26.43"/>
                    <measurement group_id="O2" value="6.17" spread="26.06"/>
                    <measurement group_id="O3" value="3.78" spread="26.12"/>
                    <measurement group_id="O4" value="8.87" spread="23.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Baseline (n=34, 30, 23, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.76" spread="39.81"/>
                    <measurement group_id="O2" value="112.16" spread="31.37"/>
                    <measurement group_id="O3" value="129.70" spread="44.64"/>
                    <measurement group_id="O4" value="128.81" spread="39.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in LDL from Endpoint (n=27, 27, 22, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.22" spread="41.05"/>
                    <measurement group_id="O2" value="1.28" spread="36.64"/>
                    <measurement group_id="O3" value="9.46" spread="32.04"/>
                    <measurement group_id="O4" value="-1.19" spread="42.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change in LDL (n=27, 27, 22, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.54" spread="33.94"/>
                    <measurement group_id="O2" value="5.15" spread="33.05"/>
                    <measurement group_id="O3" value="11.37" spread="28.57"/>
                    <measurement group_id="O4" value="3.41" spread="32.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG Baseline (n=35, 30, 23, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.81" spread="43.15"/>
                    <measurement group_id="O2" value="110.66" spread="89.64"/>
                    <measurement group_id="O3" value="131.37" spread="71.65"/>
                    <measurement group_id="O4" value="120.15" spread="66.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in TG from 24 Week Endpoint (n=27,28,22,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.37" spread="66.50"/>
                    <measurement group_id="O2" value="25.86" spread="90.32"/>
                    <measurement group_id="O3" value="-1.16" spread="49.06"/>
                    <measurement group_id="O4" value="13.85" spread="67.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change in TG (n=27, 28, 22, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.65" spread="72.42"/>
                    <measurement group_id="O2" value="40.06" spread="74.56"/>
                    <measurement group_id="O3" value="4.10" spread="36.59"/>
                    <measurement group_id="O4" value="25.95" spread="60.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increases and Decreases in Lipid Levels</title>
        <time_frame>over 24 weeks</time_frame>
        <population>Safety Population. All participants having been prescribed at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Manic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O2">
            <title>Hypomanic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 10 mg)</description>
          </group>
          <group group_id="O3">
            <title>Mixed Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O4">
            <title>Depressive Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 5 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Increases and Decreases in Lipid Levels</title>
          <population>Safety Population. All participants having been prescribed at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Least One Increase for Total Cholesterol (TC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Least One Decrease for TC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Least One Increase/Decrease for TC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients Who Increase &amp; Decrease in TC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Increase for High Density Lipoprotein (HDL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Least One Decrease for HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Least One Increase/Decrease for HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients Who Increase &amp; Decrease in HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Increase for Low Density Lipoprotein (LDL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Least One Decrease for LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Least One Increase/Decrease for LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients Who Increase &amp; Decrease in LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Least One Increase for Triglycerides (TG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Least One Decrease for TG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Least One Increase/Decrease for TG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients Who Increase &amp; Decrease in TG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to 24 Week Endpoint in Weight</title>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Safety Population. All participants having been prescribed at least one dose of study drug. Number of participants with baseline and at least one non-missing postbaseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Manic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O2">
            <title>Hypomanic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 10 mg)</description>
          </group>
          <group group_id="O3">
            <title>Mixed Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O4">
            <title>Depressive Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 5 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 24 Week Endpoint in Weight</title>
          <population>Safety Population. All participants having been prescribed at least one dose of study drug. Number of participants with baseline and at least one non-missing postbaseline value.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="2.98"/>
                    <measurement group_id="O2" value="1.91" spread="3.44"/>
                    <measurement group_id="O3" value="1.78" spread="4.43"/>
                    <measurement group_id="O4" value="2.15" spread="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Gain Compared to Baseline</title>
        <description>Weight gain at anytime more than 7%-15% or 25% of body weight compared to baseline</description>
        <time_frame>over 24 weeks</time_frame>
        <population>Safety Population. All participants having been prescribed at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Manic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O2">
            <title>Hypomanic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 10 mg)</description>
          </group>
          <group group_id="O3">
            <title>Mixed Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O4">
            <title>Depressive Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 5 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Gain Compared to Baseline</title>
          <description>Weight gain at anytime more than 7%-15% or 25% of body weight compared to baseline</description>
          <population>Safety Population. All participants having been prescribed at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Significant Gain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" spread="2.98"/>
                    <measurement group_id="O2" value="26" spread="3.44"/>
                    <measurement group_id="O3" value="18" spread="4.43"/>
                    <measurement group_id="O4" value="42" spread="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;25%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;15%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;7%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wellness Interventional Program for Weight Gain Management in Patients (for Those Who Gain at Anytime More Than 7% of Body Weight, Compared to Baseline)</title>
        <time_frame>24 weeks</time_frame>
        <population>Subgroup of patients who gained more than 7% of body weight.</population>
        <group_list>
          <group group_id="O1">
            <title>Weight Gain Subgroup</title>
            <description>Patients who gained more than 7% of body weight during the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Wellness Interventional Program for Weight Gain Management in Patients (for Those Who Gain at Anytime More Than 7% of Body Weight, Compared to Baseline)</title>
          <population>Subgroup of patients who gained more than 7% of body weight.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Advised to Consult Dietician - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Advised to Consult Dietician - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Performed a Wellness Program - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Performed a Wellness Program - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Wellnes Program Consults - 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Wellnes Program Consults - 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Wellnes Program Consults - 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients Losing Weight After Consultation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients Gaining Weight After Consultation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with Stable Weight After Consultation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MATHYS Total Score at Baseline - According to Thymic Reactivity Assessment</title>
        <description>A visual analogic scale consisting of 20 items. Items scores vary from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state), except for items 5 to 10 and 17 and 18, which are inversed and are consequently to be reversed before the analysis. Total score is sum of the 20 items and can vary from 0 to 200.</description>
        <time_frame>Baseline</time_frame>
        <population>Intention to treat. Number of participants with baseline and at least one non-missing postbaseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Thymic Hypo-Reactive</title>
            <description>As assessed by the investigator according to his clinical experience.</description>
          </group>
          <group group_id="O2">
            <title>Thymic Hyper-Reactivity</title>
            <description>As assessed by the investigator according to his clinical experience.</description>
          </group>
          <group group_id="O3">
            <title>Neither</title>
            <description>As assessed by the investigator according to his clinical experience.</description>
          </group>
        </group_list>
        <measure>
          <title>MATHYS Total Score at Baseline - According to Thymic Reactivity Assessment</title>
          <description>A visual analogic scale consisting of 20 items. Items scores vary from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state), except for items 5 to 10 and 17 and 18, which are inversed and are consequently to be reversed before the analysis. Total score is sum of the 20 items and can vary from 0 to 200.</description>
          <population>Intention to treat. Number of participants with baseline and at least one non-missing postbaseline value.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.24" spread="30.81"/>
                    <measurement group_id="O2" value="122.49" spread="32.01"/>
                    <measurement group_id="O3" value="117.26" spread="26.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 6 Week and 24 Week Endpoints in HAMA Total Scores - According to Thymic Reactivity Assessment</title>
        <description>The 14-item HAMA assesses the severity of anxiety. The investigator talked to the patient about their symptoms over the previous week before the study visit. Each item was scored using a 5-point scale, i.e. 0 = absent to 4 = severe. The total score of HAMA-14 may range from 0 (not present) to 56 (very severe).</description>
        <time_frame>Baseline, 6 Weeks, 24 Weeks</time_frame>
        <population>Intention to treat. Number of participants with baseline and at least one non-missing postbaseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Thymic Hypo-Reactivity</title>
            <description>As assessed by the investigator according to his clinical experience.</description>
          </group>
          <group group_id="O2">
            <title>Thymic Hyper-Reactivity</title>
            <description>As assessed by the investigator according to his clinical experience.</description>
          </group>
          <group group_id="O3">
            <title>Neither</title>
            <description>As assessed by the investigator according to his clinical experience.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 6 Week and 24 Week Endpoints in HAMA Total Scores - According to Thymic Reactivity Assessment</title>
          <description>The 14-item HAMA assesses the severity of anxiety. The investigator talked to the patient about their symptoms over the previous week before the study visit. Each item was scored using a 5-point scale, i.e. 0 = absent to 4 = severe. The total score of HAMA-14 may range from 0 (not present) to 56 (very severe).</description>
          <population>Intention to treat. Number of participants with baseline and at least one non-missing postbaseline value.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=30, 101, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.87" spread="7.09"/>
                    <measurement group_id="O2" value="12.63" spread="7.95"/>
                    <measurement group_id="O3" value="11.40" spread="7.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from 6 Week Endpoint (n=29, 93, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.93" spread="5.62"/>
                    <measurement group_id="O2" value="-5.96" spread="6.56"/>
                    <measurement group_id="O3" value="-4.30" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from 24 Week Endpoint (n=30, 99, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.83" spread="5.94"/>
                    <measurement group_id="O2" value="-5.65" spread="7.39"/>
                    <measurement group_id="O3" value="-6.90" spread="7.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 6 Week and 24 Week Endpoints in HAMD-17 Total Scores - According to Thymic Reactivity Assessment</title>
        <description>The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (not at all depressed) to 52 (severely depressed).</description>
        <time_frame>Baseline, 6 Weeks, 24 Weeks</time_frame>
        <population>Intention to treat. Number of participants with baseline and at least one non-missing postbaseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Thymic Hypo-Reactivity</title>
            <description>As assessed by the investigator according to his clinical experience.</description>
          </group>
          <group group_id="O2">
            <title>Thymic Hyper-Reactivity</title>
            <description>As assessed by the investigator according to his clinical experience.</description>
          </group>
          <group group_id="O3">
            <title>Neither</title>
            <description>As assessed by the investigator according to his clinical experience.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 6 Week and 24 Week Endpoints in HAMD-17 Total Scores - According to Thymic Reactivity Assessment</title>
          <description>The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (not at all depressed) to 52 (severely depressed).</description>
          <population>Intention to treat. Number of participants with baseline and at least one non-missing postbaseline value.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=29, 100, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.48" spread="7.02"/>
                    <measurement group_id="O2" value="10.64" spread="6.85"/>
                    <measurement group_id="O3" value="9.50" spread="7.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from 6 Week Endpoint (n=28, 90, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.61" spread="5.02"/>
                    <measurement group_id="O2" value="-4.89" spread="6.62"/>
                    <measurement group_id="O3" value="-4.00" spread="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from 24 Week Endpoint (n=28, 98, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.48" spread="4.32"/>
                    <measurement group_id="O2" value="-4.55" spread="7.58"/>
                    <measurement group_id="O3" value="-3.80" spread="4.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 6 Week and 24 Week Endpoints in YMRS Total Scores - According to Thymic Reactivity Assessment</title>
        <description>The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.</description>
        <time_frame>Baseline, 6 Weeks, 24 Weeks</time_frame>
        <population>Intention to treat. Number of participants with baseline and at least one non-missing postbaseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Thymic Hypo-Reactivity</title>
            <description>As assessed by the investigator according to his clinical experience.</description>
          </group>
          <group group_id="O2">
            <title>Thymic Hyper-Reactivity</title>
            <description>As assessed by the investigator according to his clinical experience.</description>
          </group>
          <group group_id="O3">
            <title>Neither</title>
            <description>As assessed by the investigator according to his clinical experience.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 6 Week and 24 Week Endpoints in YMRS Total Scores - According to Thymic Reactivity Assessment</title>
          <description>The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.</description>
          <population>Intention to treat. Number of participants with baseline and at least one non-missing postbaseline value.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=27, 101, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.48" spread="7.99"/>
                    <measurement group_id="O2" value="16.50" spread="10.65"/>
                    <measurement group_id="O3" value="10.00" spread="7.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from 6 Week Endpoint (n=26, 93, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.38" spread="7.90"/>
                    <measurement group_id="O2" value="-10.45" spread="8.46"/>
                    <measurement group_id="O3" value="-6.50" spread="4.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from 24 Week Endpoint (n=27, 99, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.70" spread="5.19"/>
                    <measurement group_id="O2" value="-11.29" spread="9.89"/>
                    <measurement group_id="O3" value="-7.60" spread="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emotional Reactivity With the Physiological Measure of Heart Rate</title>
        <description>to assess emotional reactivity with the physiological measure of heart rate, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients</description>
        <time_frame>12 weeks</time_frame>
        <population>Measures were to be collected at only one site. Not enough data to analyze.</population>
        <group_list>
          <group group_id="O1">
            <title>Manic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O2">
            <title>Hypomanic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 10 mg)</description>
          </group>
          <group group_id="O3">
            <title>Mixed Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O4">
            <title>Depressive Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 5 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Emotional Reactivity With the Physiological Measure of Heart Rate</title>
          <description>to assess emotional reactivity with the physiological measure of heart rate, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients</description>
          <population>Measures were to be collected at only one site. Not enough data to analyze.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emotional Reactivity With the Physiological Measure of Skin Conductance</title>
        <description>To assess emotional reactivity with the physiological measure of skin conductance, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients.</description>
        <time_frame>12 weeks</time_frame>
        <population>Measures were to be collected at only one site. Not enough data to analyze.</population>
        <group_list>
          <group group_id="O1">
            <title>Manic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O2">
            <title>Hypomanic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 10 mg)</description>
          </group>
          <group group_id="O3">
            <title>Mixed Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O4">
            <title>Depressive Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 5 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Emotional Reactivity With the Physiological Measure of Skin Conductance</title>
          <description>To assess emotional reactivity with the physiological measure of skin conductance, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients.</description>
          <population>Measures were to be collected at only one site. Not enough data to analyze.</population>
          <units>microvolts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emotional Reactivity With the Physiological Measure of Startle Reflex Response - Latency of Blink</title>
        <description>To assess emotional reactivity with the physiological measure of startle reflex response by measuring the latency of the blink, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients.</description>
        <time_frame>12 weeks</time_frame>
        <population>Measures were to be collected at only one site. Not enough data to analyze.</population>
        <group_list>
          <group group_id="O1">
            <title>Manic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O2">
            <title>Hypomanic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 10 mg)</description>
          </group>
          <group group_id="O3">
            <title>Mixed Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O4">
            <title>Depressive Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 5 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Emotional Reactivity With the Physiological Measure of Startle Reflex Response - Latency of Blink</title>
          <description>To assess emotional reactivity with the physiological measure of startle reflex response by measuring the latency of the blink, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients.</description>
          <population>Measures were to be collected at only one site. Not enough data to analyze.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emotional Reactivity With the Physiological Measure of Startle Reflex Response - Amplitude of Blink</title>
        <description>To assess emotional reactivity with the physiological measure of startle reflex response - by measuring the amplitude of the blink, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients.</description>
        <time_frame>12 weeks</time_frame>
        <population>Measures were to be collected at only one site. Not enough data to analyze.</population>
        <group_list>
          <group group_id="O1">
            <title>Manic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O2">
            <title>Hypomanic Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 10 mg)</description>
          </group>
          <group group_id="O3">
            <title>Mixed Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 15 mg).</description>
          </group>
          <group group_id="O4">
            <title>Depressive Episode</title>
            <description>olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks (initial dose = 5 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Emotional Reactivity With the Physiological Measure of Startle Reflex Response - Amplitude of Blink</title>
          <description>To assess emotional reactivity with the physiological measure of startle reflex response - by measuring the amplitude of the blink, recorded as a function of slides sessions from the International Affective Picture System, in a defined subgroup of patients.</description>
          <population>Measures were to be collected at only one site. Not enough data to analyze.</population>
          <units>microvolts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline MATHYS Assessment - Principal Component Analysis and Orthogonal Transformation Matrix</title>
        <description>This analysis indicates whether the total score is correct and provides enough information, or if subscores need to be calculated. Eigen value, proportion and cumulative are statistical parameters from the Principal Component Analysis, given for each factor.</description>
        <time_frame>Baseline</time_frame>
        <population>Matrix based on data from all 141 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Eigen Value</title>
          </group>
          <group group_id="O2">
            <title>Proportion</title>
          </group>
          <group group_id="O3">
            <title>Cumulative</title>
          </group>
        </group_list>
        <measure>
          <title>Baseline MATHYS Assessment - Principal Component Analysis and Orthogonal Transformation Matrix</title>
          <description>This analysis indicates whether the total score is correct and provides enough information, or if subscores need to be calculated. Eigen value, proportion and cumulative are statistical parameters from the Principal Component Analysis, given for each factor.</description>
          <population>Matrix based on data from all 141 participants.</population>
          <units>value</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Factor 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.77"/>
                    <measurement group_id="O2" value="0.4383"/>
                    <measurement group_id="O3" value="0.4383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01"/>
                    <measurement group_id="O2" value="0.1006"/>
                    <measurement group_id="O3" value="0.5389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19"/>
                    <measurement group_id="O2" value="0.0594"/>
                    <measurement group_id="O3" value="0.5984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.042"/>
                    <measurement group_id="O2" value="0.0521"/>
                    <measurement group_id="O3" value="0.6505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98"/>
                    <measurement group_id="O2" value="0.0490"/>
                    <measurement group_id="O3" value="0.6995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79"/>
                    <measurement group_id="O2" value="0.0397"/>
                    <measurement group_id="O3" value="0.7392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69"/>
                    <measurement group_id="O2" value="0.0347"/>
                    <measurement group_id="O3" value="0.7739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64"/>
                    <measurement group_id="O2" value="0.0322"/>
                    <measurement group_id="O3" value="0.8061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56"/>
                    <measurement group_id="O2" value="0.0280"/>
                    <measurement group_id="O3" value="0.8341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54"/>
                    <measurement group_id="O2" value="0.0268"/>
                    <measurement group_id="O3" value="0.8608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45"/>
                    <measurement group_id="O2" value="0.0227"/>
                    <measurement group_id="O3" value="0.8836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44"/>
                    <measurement group_id="O2" value="0.0219"/>
                    <measurement group_id="O3" value="0.9055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37"/>
                    <measurement group_id="O2" value="0.0186"/>
                    <measurement group_id="O3" value="0.9241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34"/>
                    <measurement group_id="O2" value="0.0171"/>
                    <measurement group_id="O3" value="0.9412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28"/>
                    <measurement group_id="O2" value="0.0139"/>
                    <measurement group_id="O3" value="0.9551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26"/>
                    <measurement group_id="O2" value="0.0131"/>
                    <measurement group_id="O3" value="0.9682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20"/>
                    <measurement group_id="O2" value="0.0100"/>
                    <measurement group_id="O3" value="0.9782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18"/>
                    <measurement group_id="O2" value="0.0091"/>
                    <measurement group_id="O3" value="0.9873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14"/>
                    <measurement group_id="O2" value="0.0071"/>
                    <measurement group_id="O3" value="0.9944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factor 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11"/>
                    <measurement group_id="O2" value="0.0056"/>
                    <measurement group_id="O3" value="1.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Olanzapine</title>
          <description>Olanzapine: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 8.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 8.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperprolactinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Red blood cell sedimentation rate increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Hypertonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Loss of libido</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Fewer patients than planned were enrolled in the study. Not all the analyses (Principal Component Analysis, scree plot to define the structure) could be provided due to the specific formatting of the clinicaltrials.gov databank.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

